The original AMT-130 treatment cohorts required minimum volumes in two brain regions, the caudate and putamen. Larger volumes are associated with slower disease progression. Enroll-HD did not collect the MRI measurements needed to apply the same requirement to its external controls. This raises a concern: some of the apparent treatment benefit could reflect patient selection.
In a separate analysis presented in February 2026, uniQure used TRACK-HD, TRACK-ON, and PREDICT-HD—observational studies that had measured brain volume. No AMT-130-treated patients were included in this comparison.
Margolin DH. AMT-130 slows Huntington’s disease progression at 3 years: Propensity score weighting mitigates potential bias from striatal volume absence in Enroll-HD. Presented at: CHDI 21st Annual HD Therapeutics Conference; February 24, 2026.
The researchers compared 232 patients who met the volume requirement with a larger, overlapping group of 442 selected without applying that requirement. The 232 were a subset of the 442, not a separate group.
Before adjustment, the volume-qualified subset declined by approximately 1.4 points over three years on the composite score, versus 1.7 points in the larger group. After propensity-score weighting using other baseline characteristics, both groups declined by approximately 1.4 points. UniQure argued that this shows that these other characteristics could account for the missing brain-volume information.
This is relevant evidence, but it does not establish that the adjustment adequately addressed selection bias in the actual AMT-130 analysis.
The demonstration compared hundreds of observational-study participants drawn from the same underlying studies. The treatment analysis compared just seventeen high-dose patients selected for a surgical trial with external controls from a different study. An adjustment that performs well in the first setting may not perform adequately in the second.
A much more convincing approach would be to conduct a sensitivity analysis comparing the AMT-130 patients with external controls drawn from these MRI studies who met the same brain-volume requirement as the AMT-130 patients.
This would directly test whether the apparent treatment benefit persists when both groups meet the same brain-volume requirement. It is unclear why this analysis has not yet been conducted (or presented), as it would address the brain-volume question much more directly.